VOGO M 2 10S

About

This medication combines Voglibose and Metformin, two oral antidiabetic agents with distinct mechanisms of action, to provide comprehensive glycemic control in patients with type 2 diabetes mellitus. Metformin is a biguanide that primarily reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by enhancing peripheral glucose uptake and utilization. Voglibose is an alpha-glucosidase inhibitor that delays the digestion and absorption of carbohydrates in the small intestine, thereby reducing postprandial blood glucose excursions. The synergistic action of these two drugs helps to achieve better glycemic control, particularly by targeting both fasting and postprandial hyperglycemia. This combination is often used when monotherapy with either agent is insufficient to maintain target blood glucose levels, contributing to a reduced risk of diabetes-related complications.

Uses

• Management of type 2 diabetes mellitus.
• Improvement of glycemic control.
• Reduction of postprandial hyperglycemia.
• Lowering of fasting blood glucose levels.

Directions For Use

Take this medication orally, usually with meals, as directed by your physician. Swallow the tablets whole with water.

Benefits

• Comprehensive control of blood glucose levels.
• Effective reduction of both fasting and postprandial glucose.
• Improved insulin sensitivity.
• Reduced risk of long-term diabetic complications.
• Weight-neutral or modest weight loss effect (Metformin).
• Synergistic action for enhanced efficacy.

Side Effects

• Diarrhea.
• Nausea.
• Vomiting.
• Abdominal pain.
• Flatulence.
• Indigestion.
• Metallic taste in mouth.
• Headache.
• Dizziness.
• Lactic acidosis (rare, but serious with Metformin).
• Vitamin B12 deficiency (with long-term Metformin use).
• Hypoglycemia (especially if combined with other antidiabetics).

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of lactic acidosis, a rare but serious side effect of metformin.
• Pregnancy - Generally not recommended during pregnancy. Insulin is usually preferred for glycemic control in pregnant diabetic women. Consult your doctor.
• Breastfeeding - Not recommended during breastfeeding as metformin can pass into breast milk. Voglibose safety is unknown.
• Liver - Contraindicated in patients with severe liver impairment due to increased risk of lactic acidosis with metformin. Use with caution in mild to moderate impairment.
• Kidney - Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73m²). Dose adjustment or discontinuation may be needed for moderate impairment.
• Lung - Use with caution in patients with severe lung conditions that may cause hypoxia, as this can increase the risk of lactic acidosis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.